Trials / Completed
CompletedNCT03055221
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- United Therapeutics · Industry
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravenous Treprostinil | Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration. |
Timeline
- Start date
- 2005-06-10
- Primary completion
- 2014-02-25
- Completion
- 2014-02-25
- First posted
- 2017-02-16
- Last updated
- 2024-01-05
- Results posted
- 2017-07-28
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03055221. Inclusion in this directory is not an endorsement.